Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2025)

Organogenesis Holdings has reported Capital Expenditures over the past 8 years, most recently at $4.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $4.7 million for Q4 2025, up 38.41% from a year ago — trailing twelve months through Dec 2025 was $14.2 million (up 41.06% YoY), and the annual figure for FY2025 was $14.2 million, up 41.06%.
  • Capital Expenditures for Q4 2025 was $4.7 million at Organogenesis Holdings, up from $2.2 million in the prior quarter.
  • Over the last five years, Capital Expenditures for ORGO hit a ceiling of $28.4 million in Q4 2022 and a floor of -$22.2 million in Q4 2021.
  • Median Capital Expenditures over the past 5 years was $3.3 million (2023), compared with a mean of $4.3 million.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 2080.39% in 2022 and later plummeted 4407.94% in 2023.
  • Organogenesis Holdings' Capital Expenditures stood at -$22.2 million in 2021, then surged by 227.46% to $28.4 million in 2022, then tumbled by 88.28% to $3.3 million in 2023, then grew by 1.11% to $3.4 million in 2024, then skyrocketed by 38.41% to $4.7 million in 2025.
  • The last three reported values for Capital Expenditures were $4.7 million (Q4 2025), $2.2 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.